Tislelizumab as Cross-line Treatment for Advanced NSCLC

Clinical trial NCT05192681 · UNKNOWN

Trial details

NCT number: NCT05192681
Sponsor: Fujian Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Non-small-cell Lung Cancer

Start date: 2021-10-10
Primary completion: 2023-10-10
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.